Publication at First Faculty of Medicine |
2015
Abstract
Biological therapy has become an part of the treatment of rheumatic diseases. Golimumab belongs to the group of inhibitors of tumor necrosis factor (TNFa) and is used in the treatment of rheumatoid arthritis, ankylosing spondylitis and pso- riatické arthritis.
It is a fully human monoclonal antibody that is administered at monthly intervals. This work summarizes pharmacokinetic properties and indications of golimumab and its effectiveness will be presented at two selected case reports of patients with rheumatoid arthritis and ankylosing spondylitis.